Research and Markets (http://www.researchandmarkets.com/research/cc3342/global_testicular)
has announced the addition of the "Global
Testicular Cancer Drugs Market 2014-2018" report to their
One of the key drivers is the increasing prevalence of testicular cancer
due to a variety of factors such as congenital abnormalities, family
history, abnormal testicular development, and HIV infection. This has
increased the demand for testicular cancer drugs as these drugs have
greatly improved survival rate for patients with both seminomas and
non-seminomas type of testicular cancer.
The current trend witnessed by the Global Testicular Cancer Drugs market
is combination therapy being used for treating testicular cancer.
Several oncologists believe that chemotherapy drugs are most effective
when given in combination with radiation therapy and surgery. Cancer
cells that are confined locally can be easily treated by surgery or
radiation therapy, while cancer cells that have spread to distant sites
can be killed by chemotherapy. Therefore, combination therapy helps in
completely removing the tumor or destroying the cancerous cells in the
patient's body. The combination therapy is decided depending on the size
of the tumor and the risk of recurrence. Moreover, for treatment of
testicular cancer, a combination of two or more drugs is usually given.
Some of the combinations are BEP, EP (etoposide and cisplatin), and VIP
(vinblastine plus ifosfamide and cisplatin).
Further, the report states that one of the main challenges in the market
is the presence of alternative testicular cancer treatments that do not
use drugs, thereby limiting the consumption of drugs.
Key vendors dominating this space include:
Other vendors mentioned in the report are:
Key Topics Covered:
For more information visit http://www.researchandmarkets.com/research/cc3342/global_testicular
[ Back To NFVZone's Homepage ]